Lyric Bio develops palm‑sized bioreactors that use a proprietary laser‑printed cellular substrate to grow donor‑derived B cells at ultra‑high density, enabling continuous production of human immunoglobulin from a single plasma donation. This tissue‑engineered platform can generate thousands of IVIg doses per donor, reducing reliance on plasma collection, lowering manufacturing costs, and improving product consistency for pharmaceutical manufacturers and healthcare providers.
Funding
Funding not disclosed
Founders
Product
Problem
Current production of human immunoglobulin (Ig) therapies relies on plasma donations, requiring roughly ten donations to generate a single dose of IVIg. This dependence creates supply constraints, high manufacturing costs, and variability in product quality, limiting access to life‑saving treatments for many patients.
Solution
Lyric Bio develops compact bioreactors that mimic human tissue to grow donor‑derived B cells at ultra‑high density, enabling continuous production of human Ig from a single donor. The reactors use a proprietary laser‑printed cellular substrate that supports rapid cell expansion, allowing a single donation to yield thousands of therapeutic doses. By shifting Ig manufacturing from plasma collection to scalable tissue‑engineered bioprocessing, Lyric reduces reliance on blood donations, lowers production costs, and improves product consistency. The palm‑sized bioreactors can be deployed in manufacturing facilities to create a stable, on‑demand supply of high‑quality immunoglobulin for a broad range of clinical indications.
Target Audience
Primary customers are pharmaceutical and biotech manufacturers of immunoglobulin therapies, as well as healthcare providers seeking a reliable, cost‑effective source of high‑quality IVIg and related products.
Features
- Proprietary laser‑printed cellular substrate that enables ultra‑high‑density B‑cell growth
- Palm‑sized, self‑contained bioreactor platform for continuous Ig production from a single donor
- Scalable tissue‑engineering process capable of generating 1,000+ doses per donation
- Integrated manufacturing workflow that reduces the need for large‑volume plasma collection and transport
- Enhanced product consistency and quality control through controlled cell culture conditions
- Potential to lower overall therapy costs and improve supply chain stability